Matched sibling donor stem cell transplantation for sickle cell disease: Results from the Spanish group for bone marrow transplantation in children.
Maria Isabel Benítez-CarabanteCristina BeléndezMarta González-VicentLaura Alonso GarcíaMaría Luz Uría-OficialdeguiMonserrat TorrentJosé María Pérez-HurtadoJosé Luis FusterElena CelaCristina Díaz-de-Heredianull nullPublished in: European journal of haematology (2021)
An early referral to HSCT centers should be proposed early in life, before severe complications occur. MSD HSCT should be considered a curative option for all patients aged ≤ 5 years and for older pediatric patients who present complications derived from the disease.
Keyphrases
- stem cell transplantation
- sickle cell disease
- bone marrow
- end stage renal disease
- high dose
- prognostic factors
- newly diagnosed
- ejection fraction
- risk factors
- chronic kidney disease
- mesenchymal stem cells
- peritoneal dialysis
- primary care
- hematopoietic stem cell
- physical activity
- early onset
- stem cells
- low dose
- middle aged
- community dwelling
- patient reported
- drug induced